Loading...
OTCM
APTCF
Market cap149kUSD
Jul 28, Last price  
0.00USD
Name

Advanced Proteome Therapeutics Corporation

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
683,711579,294058,93094,47950,7668,6284,350000000000000
Net income
0k
-100.00%
-65,5072,628,406-1,166-1,895,890-1,135,482-974,160-1,147,231-1,081,499-756,172-1,021,103-1,149,980-886,860-867,448-721,720-744,773-333,466-450,636-1,834,556759,6150
CFO
0k
P
198,56134,687-1,166-765,398-1,091,147-905,305-901,628-894,259-543,935-772,493-883,340-1,006,463-804,313-732,837-1,212,312-685,704-466,981-545,199-693,5790

Profile

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. The company develops and commercializes a platform for the chemical modification of protein therapeutics. Its platform is dedicated to applications in the field of antibody drug conjugates, as well as focused on protein conjugates and immunomodulation. The company is headquartered in Burnaby, Canada.
IPO date
Apr 04, 1994
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑072022‑072021‑072020‑072019‑072018‑072017‑072016‑072015‑07
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT